2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-137083
    Trifluoperazine N-Glucuronide 165602-90-4
    Trifluoperazine N-Glucuronide (UGT1A4), as one of the human UGT1A isoforms, is expressed in the liver. Trifluoperazine N-Glucuronide catalyzes the imipramine and trifluoperazine Nglucuronide formation.
    Trifluoperazine N-Glucuronide
  • HY-13948B
    Angiotensin II human TFA 2761969-44-0 98.29%
    Angiotensin II human (Angiotensin II) TFA is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system. Angiotensin II human TFA plays a central role in regulating human blood pressure, which is mainly mediated by interactions between Angiotensin II and the G-protein-coupled receptors (GPCRs) Angiotensin II type 1 receptor (AT1R) and Angiotensin II type 2 receptor (AT2R). Angiotensin II human TFA stimulates sympathetic nervous stimulation, increases aldosterone biosynthesis and renal actions. Angiotensin II human TFA induces growth of vascular smooth muscle cells, increases collagen type I and III synthesis in fibroblasts, leading to thickening of the vascular wall and myocardium, and fibrosis. Angiotensin II human TFA also induces apoptosis. Angiotensin II human TFA induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway.
    Angiotensin II human TFA
  • HY-15398A
    5,6-trans-Vitamin D3 22350-41-0 99.81%
    5,6-trans-Vitamin D3 (5,6-trans-Cholecalciferol;5,6-trans-Colecalciferol) is a photoproduct of vitamin D3. Vitamin D3 is a naturally occuring form of vitamin D. Vitamin D3 induces cell differentiation and prevents proliferation of cancer cells.
    5,6-trans-Vitamin D3
  • HY-155642
    PU-48 335394-78-0 99.76%
    PU-48 is a blood-brain barrier-permeable urea transporter (UT) inhibitor with an IC50 of 0.32 μM against rat UT-A. By functionally inhibiting urea transporters (including UT-A subtypes) in the renal inner medullary collecting ducts, PU-48 induces urea-selective diuresis. PU-48 does not alter blood levels of sodium, potassium or chloride ions, nor does it affect the excretion of non-urea solutes. PU-48 shows no significant toxicity in cell or animal models and can be used in edema-related research.
    PU-48
  • HY-156193
    PF-07208254 2573122-40-2 98.46%
    PF-07208254 is a selective, orally active allosteric inhibitor of branched-chain ketoacid dehydrogenase kinase (BDK) (IC50=110 nM, Ki=54 nM, KD=84 nM). PF-07208254 inhibits BDK-mediated BCKDH phosphorylation and enhances the catabolism of branched-chain amino acids (BCAAs) and branched-chain keto acids (BCKAs) by binding to the allosteric pocket of BDK, reducing BDK binding to BCKDH-E2 and promoting BDK degradation. PF-07208254 inhibits BDK activity in human skeletal muscle cells (IC50=540 nM) and has activity to improve cardiac function and metabolism. PF-07208254 can be used in the study of cardiometabolic diseases (e.g., heart failure, type 2 diabetes).
    PF-07208254
  • HY-163436
    F44-A13 1338190-14-9
    F44-A13 is an orally active and highly selective farnesoid X receptor (FXR) antagonist with an IC50 value of 1.1 μM. F44-A13 can optimize cholesterol metabolism and reduce its activity by inducing CYP7A1 expression. F44-A13 reduces levels of cholesterol, triglycerides, and low-density lipoprotein cholesterol (LDL-C) in mouse models. F44-A13 can be used in the study of metabolic diseases associated with lipid disorders.
    F44-A13
  • HY-164027
    MyoMed 205 2614161-13-4 99.31%
    MyoMed 205 is an orally active muscle ring finger protein 1 (MuRF1) inhibitor. MyoMed-205 reduces ubiquitination and subsequent proteasomal degradation of muscle proteins by inhibiting MuRF1 activity. MyoMed 205 augments muscle performance, attenuates muscle weight loss and alleviates disease-induced weight loss. MyoMed 205 can be used for the research of cancer cachexia, type 2 diabetes mellitus, and heart failure with preserved ejection fraction.
    MyoMed 205
  • HY-164774
    (4S)-GLP-1 receptor agonist 14 2758659-09-3 99.62%
    (4S)-GLP-1 receptor agonist 14 is a potent and orally active GLP-1 receptor agonist with an EC50 ≤ 20 nM. (4S)-GLP-1 receptor agonist 14 can be used for research on diabetes, obesity, metabolic diseases, cardiovascular diseases, liver diseases, nonalcoholic steatohepatitis (NASH), and other diseases associated with GLP-1 receptor.
    (4S)-GLP-1 receptor agonist 14
  • HY-170538
    SNT-5382 2125956-92-3 99.96%
    SNT-5382 is a lysyl oxidase family (LOX) inhibitor and anti-fibrotic agent. SNT-5382 binds to the LTQ cofactor of LOXL2 and inhibits the enzymatic activities of LOXL3, LOXL4, LOXL1, CYP2C9, and CYP2C19. SNT-5382 reduces cardiac and liver fibrosis as well as collagen crosslinks, and improves cardiac function. SNT-5382 can be used for the research of heart failure, myocardial infarction, and nonalcoholic steatohepatitis-related liver fibrosis.
    SNT-5382
  • HY-17623C
    (R)-Tegoprazan 942195-56-4 99.73%
    (R)-Tegoprazan ((R)-CJ-12420; example 3), a benzimidazole derivative, is a potent kidney H+/K+-ATPase inhibitor with an IC50 of 98 nM of canine kidney Na+/K+-ATPase. (R)-Tegoprazan has the potential for gastrointestinal diseases research.
    (R)-Tegoprazan
  • HY-B0876A
    Fomepizole hydrochloride 56010-88-9 99.85%
    Fomepizole (4-Methylpyrazole) hydrochloride is a potent and orally active cytochrome P450 (CYP2E1) inhibitor. Fomepizole hydrochloride is a competitive inhibitor of the enzyme alcohol dehydrogenase. Fomepizole hydrochloride blocks further conversion of methanol and ethylene glycol to toxic metabolites. Fomepizole hydrochloride has the potential for an antidote for ethylene glycol or methanol poisoning.
    Fomepizole hydrochloride
  • HY-B2235C
    L-α-Lecithin (soybean) 8002-43-5
    L-α-Lecithin (soybean) is an orally active phospholipid. L-α-Lecithin (soybean) increases the bioavailability of Lutein in plasma and eyes of Rattus norvegicus, enhances plasma Glutathione peroxidase activity, and regulates fatty acids in plasma and tissues.
    L-α-Lecithin (soybean)
  • HY-P1021A
    Peptide YY (PYY) (3-36), porcine TFA 99.97%
    Peptide YY (PYY) (3-36), porcine TFA is a gut hormone peptide that acts as a Y2 receptor agonist to reduce appetite.
    Peptide YY (PYY) (3-36), porcine TFA
  • HY-P10271
    RG7697 99.90%
    RG7697 is a dual agonist for glucagon-like peptide receptor (GLP Receptor) and glucosedependent insulinotropic polypeptide receptor (GIPR), with EC50 of 5 and 3 pM, respectively. RG7697 exhibits antihyperglycemic property.
    RG7697
  • HY-P5069A
    Glutathione diethyl ester TFA
    Glutathione diethyl ester (TFA) is a delivery agent for glutathione monoester, and thus for glutathione, in human cells and therefore could serve to decrease oxidative stress and toxicity.
    Glutathione diethyl ester TFA
  • HY-Y1069S
    (S)-Malic acid-d3 59652-74-3 99.64%
    (S)-Malic acid-d3 is the deuterium labeled (S)-Malic acid. (S)-Malic acid ((S)-2-Hydroxysuccinic acid) is a dicarboxylic acid in naturally occurring form, contributes to the pleasantly sour taste of fruits and is used as a food additive.
    (S)-Malic acid-d3
  • HY-116374A
    Glycolithocholic acid sodium 24404-83-9 98.0%
    Glycolithocholic acid (Lithocholylglycine) sodium is the sodium salt of Glycolithocholic acid. Glycolithocholic acid is a glycine-conjugated secondary bile acid. Glycolithocholic acid can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC).
    Glycolithocholic acid sodium
  • HY-124124S
    N-Methylnicotinamide-d4 2708278-64-0 98.23%
    N-Methylnicotinamide-d4 is the deuterium labeled N-Methylnicotinamide (HY-124124). N-Methylnicotinamide is an endogenous metabolite with antithrombotic effect. N-Methylnicotinamide via production/release of prostacyclin inhibits arterial thrombosis development. N-Methylnicotinamide is also the N-methylation product from nicotinamide catalyzed by N-methyltransferase within nicotinate and nicotinamide metabolism pathway.
    N-Methylnicotinamide-d4
  • HY-125731S
    Glycodeoxycholic acid-d4 1069132-37-1 99.90%
    Glycodeoxycholic acid-d4 is the deuterium labeled Glycodeoxycholic Acid. Glycodeoxycholic Acid is an endogenous metabolite.
    Glycodeoxycholic acid-d4
  • HY-125857A
    Cytochrome C (equine heart) 9007-43-6 99.1%
    Cytochrome C (equine heart) is composed of 104 amino acids and is a nuclear-encoded mitochondrial protein. Cytochrome C (equine heart) is involved in mitochondrial electron transport and intrinsic type II apoptosis. Cytochrome C (equine heart) can act as a single electron carrier.
    Cytochrome C (equine heart)
Cat. No. Product Name / Synonyms Application Reactivity